Tag
A multicenter Chinese registry study demonstrates that direct oral anticoagulants are noninferior to warfarin in preventing 1-year symptomatic recurrent venous thromboembolism after cerebral venous thrombosis, with exploratory bleeding outc
This study evaluates the real-world effectiveness and safety of direct oral anticoagulants versus warfarin in Asian patients with atrial fibrillation and mitral stenosis, revealing higher stroke yet lower myocardial infarction risk with DOA
In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.
In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored
A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional
The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.
A 75-year-old male on warfarin presented with spontaneous thigh swelling and pain, diagnosed as spontaneous intramuscular hematoma, successfully managed with supportive care and warfarin reversal.
Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remain
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id
